Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Fresenius Medical Care AG & Co. KGaA FMS stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Fresenius Medical has a trailing twelve months PE ratio of 13.58, as you can see in the chart below:
This level actually compares favorably with the market at large, as the PE for the S&P 500 stands at about 17.85. If we focus on the long-term PE trend, Fresenius Medical’ current PE level puts it below its midpoint of 21.94 over the past five years, with the number having risen rapidly over the past few months. However, the current level stands below the highs for the stock, suggesting that it can be a solid entry point.
However, the stock’s PE also compares favorably with the Zacks Medical Market sector’s trailing twelve months PE ratio, which stands at 20.59. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Fresenius Medical has a forward PE ratio (price relative to this year’s earnings) of 14.40, so it is fair to expect an increase in the company’s share price in the near future.
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Fresenius Medical has a P/S ratio of about 1.06. This is much lower than the S&P 500 average, which comes in at 3.15 right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
Broad Value Outlook
In aggregate, Fresenius Medical currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Fresenius Medical a solid choice for value investors.
For example, the PEG ratio for Fresenius Medical is just 2.45, a level that is slightly lower than the industry average of 2.47. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Additionally, P/CF ratio (another great indicator of value) comes in at 9.12, which is marginally better than the industry average of 21.63. Clearly, FMS is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Fresenius Medical might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of B and Momentum Score of C. This gives FMS a Zacks VGM score — or its overarching fundamental grade — of A. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed at the best. The current quarter has seen one upward revision in the past sixty days compared to no downward revision, while the current year estimate has seen one upward revision compared to two downward revisions in the same time period.
As a result, the current quarter consensus estimate rose 3.5% in the past two months, whereas the current year estimate declined 2.92%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Fresenius Medical Care AG & Co. KGaA Price and Consensus
Fresenius Medical Care AG & Co. KGaA price-consensus-chart | Fresenius Medical Care AG & Co. KGaA Quote
Owing to the bearish estimate trends, the stock carries a Zacks Rank #3 (Hold), which is why we are looking for in-line performance from the company in the near term.
Fresenius Medical is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a Zacks Rank #3 it is hard to get too excited about this company overall. In fact, over the past one year, the broader industry has underperformed the market at large, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
It’s Illegal in 42 States, But Investors Will Make Billions Legally
In addition to the companies you read about above, today you get details on the newly-legalized industry that’s tapping into a “habit” that Americans spend an estimated $150 billion on every year.
That’s twice as much as they spend on marijuana, legally or otherwise.
Zacks special report revealing how investors can profit from this new opportunity. As more states legalize this activity, the industry could expand by as much as 15X. Zacks’ has just released a Special Report revealing 5 top stocks to watch in this space.
See these 5 “sin stocks” now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research